Literature DB >> 3393384

Airway obstruction and airway wall instability in cystic fibrosis: the isolated and combined effect of theophylline and sympathomimetics.

E Eber1, B Oberwaldner, M S Zach.   

Abstract

Multiple aspects of lung function were measured in 17 cystic fibrosis (CF) patients on four occasions: without therapy (0); with oral theophylline medication (Th); after inhalation of salbutamol (beta 2); and with combined medication (Th + beta 2). In addition to routine measurements, partial and maximum expiratory flow-volume (MEFV) curves were superimposed, and the flow transient equivalent of the MEFV curve was determined. Its volume dimension (volume of airway contribution, VACMEFV) partially reflects airway distensibility. Changes in airway compressibility--the other consequence of airway wall instability--were assessed by observing changes in end-expiratory flow rate. Airway resistance, expired volumes, and early expired flow rates, as well as VACMEFV improved significantly after beta 2 medication. Mean end-expiratory flow also increased after beta 2; in two patients, however, it decreased significantly, indicating that enhanced airway compression dominated over the release of bronchospasm. The alone had only minor effects on lung function. Early expired volume and flow rates as well as VACMEFV showed no significant difference between beta 2 alone and Th + beta 2; airway resistance even decreased significantly with this drug combination. End-expiratory flow rate, however, was significantly lower after Th + beta 2 than after beta 2 alone. Although theophylline does not alter lung function in most patients with CF, sympathomimetics relieve bronchospasm in many, but they enhance airway compressibility and thereby decrease peripheral expiratory airflow in some.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3393384     DOI: 10.1002/ppul.1950040404

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  11 in total

Review 1.  Cystic fibrosis--an Indian perspective on recent advances in diagnosis and management.

Authors:  S K Kabra; M Kabra; M Ghosh; I C Verma
Journal:  Indian J Pediatr       Date:  1996 Mar-Apr       Impact factor: 1.967

Review 2.  Bronchodilators in cystic fibrosis.

Authors:  P L Brand
Journal:  J R Soc Med       Date:  2000       Impact factor: 5.344

Review 3.  Asthma in cystic fibrosis.

Authors:  Ian M Balfour-Lynn
Journal:  J R Soc Med       Date:  2003       Impact factor: 5.344

Review 4.  "CF asthma": what is it and what do we do about it?

Authors:  I M Balfour-Lynn; J S Elborn
Journal:  Thorax       Date:  2002-08       Impact factor: 9.139

Review 5.  Pathogenesis and management of lung disease in cystic fibrosis.

Authors:  M S Zach
Journal:  J R Soc Med       Date:  1991       Impact factor: 5.344

6.  Bronchial constriction after nebulized tobramycin preparations and saline in patients with cystic fibrosis.

Authors:  W H Nikolaizik; V Jenni-Galović; M H Schöni
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

Review 7.  Nebulised bronchodilators, corticosteroids, and rhDNase in adult patients with cystic fibrosis.

Authors:  S P Conway; A Watson
Journal:  Thorax       Date:  1997-04       Impact factor: 9.139

Review 8.  Treatment of severe small airways disease in children with cystic fibrosis: alternatives to corticosteroids.

Authors:  Adam Jaffe; Ian M Balfour-Lynn
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

9.  Primary ciliary dyskinesia: evolution of pulmonary function.

Authors:  J Hellinckx; M Demedts; K De Boeck
Journal:  Eur J Pediatr       Date:  1998-05       Impact factor: 3.183

10.  Self-administered chest physiotherapy in cystic fibrosis: a comparative study of high-pressure PEP and autogenic drainage.

Authors:  A Pfleger; B Theissl; B Oberwaldner; M S Zach
Journal:  Lung       Date:  1992       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.